Growth Metrics

West Pharmaceutical Services (WST) EPS (Weighted Average and Diluted) (2016 - 2026)

West Pharmaceutical Services has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at $1.92 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 56.1% to $1.92 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.48 through Mar 2026, up 17.43% year-over-year, with the annual reading at $6.79 for FY2025, 1.49% up from the prior year.
  • EPS (Weighted Average and Diluted) was $1.92 for Q1 2026 at West Pharmaceutical Services, up from $1.82 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $2.48 in Q2 2022 and troughed at $1.23 in Q1 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is $1.83 (2023), against an average of $1.82.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 31.17% in 2022 and later skyrocketed 56.1% in 2026.
  • Tracing WST's EPS (Weighted Average and Diluted) over 5 years: stood at $1.37 in 2022, then skyrocketed by 33.58% to $1.83 in 2023, then dropped by 2.73% to $1.78 in 2024, then grew by 2.25% to $1.82 in 2025, then increased by 5.49% to $1.92 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $1.92, $1.82, and $1.92 for Q1 2026, Q4 2025, and Q3 2025 respectively.